CD45 Antibody, anti-human, REAfinity™
Synonyms: Ptprc, GP180, L-CA, LY5, T200
RECOMBINANT EXTENDED VALIDATION
Bioz Star97/100 Bioz rating
313 Citations55 Images
Clone:
REA747 | 5B1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, 3D-IF, IF, IHC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD45 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 615
PE-Vio 670
PE-Vio 770
PerCP-Vio 700
Vio Bright B515
Vio Bright R667
Vio Bright R720
Vio Bright V423
Vio Bright V600
Vio Bright V646
Vio Bright V710
Vio Bright V787
VioBlue
VioGreen
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-114-568, 130-110-771, 130-110-633
Description:
Human peripheral blood cells after erythrocyte lysis were stained with CD45 antibodies or with the corresponding REA Control (S) antibodies (left images). Flow cytometry was performed using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC, ICC
Conjugate:
APC
Used products:
130-114-568, 130-110-771, 130-110-633
Testing grade:
3D-Immunofluorescence applications
Vio R667
Tissue clearing:
MACS® Clearing Kit
Fixation:
PFA
Species tested:
human
Tissue used:
ovarian cancer
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
Vio R667
Used products:
130-128-742
Description:
3D-immunofluorescence analysis of human ovarian cancer fixed with 4% PFA and subjected to whole-mount immunostaining with CD45 Antibody, anti-human, Vio R667 (red). The sample was processed and optically cleared using the MACS® Clearing Kit and imaged with an UltraMicroscope Blaze light sheet instrument. Sample detail image (A), overview image (B), 3D-rendering (C, autofluorescence in gray) and 3D-rendered video (autofluorescence in gray). Scale bars: 20 µm (A, C), 100 µm (B).

A

Application imageView details view details

B

Application imageView details view details

C

Application imageView details view details
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-122-311
Extended validation for CD45 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA747
5B1
high
2D1
high
HI30
high
MB4-6D6
low
REA1023
low
REAL258
high

Cells were incubated with an excess of purified unconjugated CD45 (REA747) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD45 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD45-PE (REA747, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of human CD45 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD45-PE, clone (REA747). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD45. Human peripheral blood mononuclear cells (PBMCs) were stained with CD45 antibodies and plotted against the side scatter. As a control, CD45 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for CD45 Antibody, anti-human, REAfinity™
Overview

Clone REA747 recognizes the human CD45 antigen, a member of the protein tyrosine phosphatase (PTP) family, also known as the leukocyte common antigen (LCA). The CD45 molecule is a type I transmembrane protein which is required for T and B cell activation and involved in cell growth, differentiation, mitotic cycle, and oncogenic transformation. CD45 is expressed in different isoforms (CD45RA, CD45RB, CD45RC, CD45RAB, CD45RAC, CD45RBC, CD45RO, CD45R (ABC)) depending on the differentiation status of the cell. The CD45 antibody recognizes a common epitope of all CD45 isoforms.

Additional information: Clone REA747 displays negligible binding to Fc receptors.

Alternative names

Ptprc, GP180, L-CA, LY5, T200

Detailed product information

Technical specifications

Clone
REA747
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD45
Molecular mass of antigen [kDa]
145
Distribution of antigen
T cells, B cells, dendritic cells, Langerhans cells, mast cells, monocytes, macrophages, leukocytes, lymphocytes, thymocytes, hematopoietic stem and progenitor cells
Entrez Gene ID
RRID
AB_2658238, AB_2905022, AB_2658249, AB_2658255, AB_2658257, AB_2658256, AB_2658248, AB_2658241, AB_2658245, AB_2658243, AB_2658246, AB_2751046, AB_2658242, AB_2658253, AB_2658254, AB_2658237, AB_2658244, AB_2726700, AB_2928475, AB_2658251, AB_2658239, AB_2658250, AB_2801892, AB_2658236, AB_2658240, AB_2751047, AB_2658247, AB_2658252

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD45 Antibody, anti-human, REAfinity™
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?